Search This Blog

Monday, March 2, 2026

Xeris beats, issues guidance

 

Xeris Biopharma beats Q4 estimates with non-GAAP EPS $0.06 and revenue $83.4M, issues 2026 revenue guidance of $375–$390M

  • Company reports a move to net profitability alongside record Q4 and full-year 2025 results.
  • 2026 outlook also calls for higher adjusted EBITDA.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)